Nobel Prize in Chemistry Awardee and Distinguished Professor Mario Molina will be remembered for dedicating his life to research and working to protect our environment.
UC San Diego’s Center for Energy Research has been awarded two grants from the Department of Energy for research focused on developing environment-friendly and cost-competitive energy sources and systems.
The launch of the Institute for Materials Discovery and Design at UC San Diego featured a keynote address by Nobel Laureate Stanley Whittingham and researches shared how materials science can help provide solutions for climate change, public health and equal access to food and water.
UC San Diego School of Medicine researchers report that older adults are increasingly using cannabis to treat a variety of common health conditions, including pain, sleep disturbances and psychiatric conditions like anxiety and depression.
A team from the San Diego Supercomputer Center at UC San Diego contributed to a study led by the Vanderbilt Vaccine Center on T cell receptors, which play a vital role in alerting the adaptive immune system to mount an attack on invading foreign pathogens, including Coronavirus SARS-CoV-2.
J. Silvio Gutkind, PhD, has been named chair of the Department of Pharmacology at UC San Diego School of Medicine.
Project focuses on lipids (fat molecules) as the starting point to understand the evolution of eukaryotic cells, carrying implications for human health and disease
Two University of California San Diego researchers have received prestigious awards through the 2020 National Institutes of Health (NIH) High-Risk, High-Reward Research Program.
Patients receiving care for advanced cancer at Moores Cancer Center at UC San Diego Health were more likely to survive or experience a longer period without their disease progressing if they received personalized cancer therapy.
UC San Diego Health will be a test site for a third, major Phase III clinical trial to assess a vaccine candidate for the novel coronavirus that causes COVID-19. Sponsored by Janssen Pharmaceuticals, the trial will recruit up to 60,000 participants at sites in the United States and worldwide.